1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Personalized Medicine and Epigenomics: Technologies and Global Markets

This BCC Research report discusses the global epigenomic market in terms of growth, size and opportunities with regard to different therapies, technologies, as well as regionally. The report includes forecasted trends and revenue through 2020.

Use this report to:

Gain insight into the global market for epigenomics, including emerging opportunities in biomarkers, diagnostics and therapeutics.
Assess global epigenomic market by types, application areas, products, segments, and regions.
Identify market trends, issues and factors impacting the epigenomic market.

Highlights

The global epigenomic market reached nearly $4 billion in 2014 and $4.7 billion in 2015. The market should reach nearly $12.1 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 20.6% from 2015 to 2020.

North America dominated the global epigenomic market and reached $1.9 billion in 2015.

The market should reach $4.6 billion in 2020 at a CAGR of 19.9% from 2015 to 2020.

The Asia-Pacific epigenomic market reached nearly $1.0 billion in 2015, and should reach $2.8 billion by 2020 growing at a CAGR of 22.8% throughout the period.

INTRODUCTION

The report Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics discusses the global epigenomic market in terms of growth, size and opportunities with regard to different therapies, technologies, as well as regionally. The report includes forecasted trends and revenue through 2020. Major players, innovative products and technologies, trends and market dynamics, competitive intelligence and
regional trends are well-researched and analyzed.

STUDY GOALS AND OBJECTIVE

Define and discuss the global market for epigenomics, including emerging opportunities in biomarkers, diagnostics and therapeutics.
Analyze market structure by segments and subsegments.
Estimate market revenues by regions and products.
Identify market trends, issues and factors impacting the epigenomic market.
Explain opportunities with respect to regions and products.
Profile major players and analyze their core competencies and strategies.
Track alliances, joint ventures, mergers and acquisitions, new product developments, and research and development.

TITLE DESCRIPTION

The term epigenetics refers to the study of alterations in genes that are not facilitated by any change in DNA sequence. Epigenetics is essential for the development of mammals due to its benefits and threats. Epigenetic regulation is a key factor for the development of mammals and cellular differentiation. On the contrary, epigenetic dysregulation results in diseases, including cancer and various other genetic disorders.

The human genome consists of DNA, which is responsible for encoding genetic information. Epigenomes include histone and DNA modification layered on top of the genome. These are responsible for directing the genome to feed information to genes during particular events. The epigenetic condition of a cell is affected by both developmental and environmental factors, including nutrition, toxins, infection and drugs of abuse. Thus, epigenetics exhibits a close relationship between environment and genome.

The study of epigenetics has evolved over the years, leading to rapid changes on the technological front. Epigenetic study using DNA sequencing technology has enabled researchers to perform large-scale experiments as compared to micro-array approaches. Constant evolution in technology, including the adoption of more advanced sequencing techniques, is expected to assist researchers to perform experiments at supreme resolutions.

SCOPE OF THE REPORT

The report will analyze the market by types, products and applications. It will also focus on emerging technologies and therapies. Geographically, the market is divided into five regions: North America, Europe, the Asia-Pacific region and Latin America, and the Middle East and Asia (MEA).

Products are segmented by reagents, kits, instruments, enzymes and services.

Technologies are segmented by DNA methylation, histone methylation and acetylation, MicroRNA modification.
Applications are segmented areas by diagnosis, prognosis, therapy optimization in routine clinical treatment and drug discovery.

Therapy areas are segmented by cancer treatment, neurological disorders, CVD and others, which includes the research and development (R&D) stage.

Cancer treatment is further broken down into hematological cancers, solid tumors, gastric cancer, lung cancer and others.



Table Of Contents

Personalized Medicine and Epigenomics: Technologies and Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVE 2
TITLE DESCRIPTION 2
SCOPE OF THE REPORT 3
INTENDED AUDIENCE 3
RESEARCH METHODOLOGY 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL EPIGENOMIC MARKET BY REGION, 2014-2020 ($
MILLIONS) 7
CHAPTER 3 MARKET OVERVIEW 9
INTRODUCTION 9
NEW PARADIGM OF EPIGENOMICS 9
EPIGENOMICS AS IT FITS WITHIN GENOMICS 10
TECHNICAL SCOPE OF THIS REPORT 10
EPIGENOMIC MARKET POTENTIAL 11
EPIGENOMIC PRODUCTS 11
RESEARCH TOOLS AND REAGENTS 11
DIAGNOSTICS 12
DRUGS 13
TABLE 1 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC
THERAPIES 13
TABLE 2 SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT 15
GROWTH DRIVING FORCES 15
GROWTH IN LIFE SCIENCE FUNDING 16
EPIGENOMIC MAP CREATION 16
AGING POPULATIONS IN DEVELOPED COUNTRIES 17
NEED FOR BETTER CANCER THERAPIES 17
GROWTH IN PERSONALIZED MEDICINE 18
IMPORTANCE OF EPIGENETIC TECHNOLOGY 18
LIFECYCLE STATUS OF EPIGENOMIC TECHNOLOGIES 18
HISTORICAL BACKGROUND 18
EPIGENOMIC INDUSTRY 19
CHAPTER 4 EPIGENETIC DRUGS ON THE MARKET AND IN THE PIPELINE 21
OVERVIEW 21
DRUG CLASSIFICATION 21
TABLE 3 EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL 21
DNMT INHIBITORS 22
Nucleoside Analogue Inhibitors 22
Non-Nucleoside Analogue Inhibitors 22
Antisense Oligonucleotides 23
TABLE 4 CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND
DEVELOPMENTAL PHASES, 2005-2015 23
DNA METHYLATION 24
DNA Methyltransferases 24
FIGURE 1 AZAC AND 5-AZADC MECHANISM OF ACTION 24
HISTONE DEACETYLASE INHIBITORS 25
Histone Deacetylase Inhibitors' Roles in Mental Health 25
Histone Deacetylase Inhibitors Roles in Other Health Conditions 26
Epigenetic Drug Combinations 26
FIGURE 2 EPIGENETIC CHANGES IN CANCER INVOLVING THE METHYLATION OF
TUMOR-SUPPRESSION GENES AND THE DEMETHYLATION OF PROMETASTATIC
GENES
26
EMERGING THERAPIES 27
LARGE-SCALE REGIONAL EPIGENOMIC PROJECTS 27
ENCYCLOPEDIA OF DNA ELEMENTS 28
INTERNATIONAL HUMAN EPIGENOME CONSORTIUM 29
Blueprint 30
Epigenomic Platform Program (Canada) 31
DEEP (Germany) 31
CREST/IHEC, Team Japan (Asia) 32
National Institutes of Health Roadmap Epigenomic Project 32
OTHER REGIONAL PROJECTS 33
Asia-Pacific Projects 33
Canadian and Australian Projects 33
European Epigenomic Projects 33
CHAPTER 5 PERSONALIZED MEDICINE BASED ON THERAPEUTICS 35
OVERVIEW 35
MARKET DYNAMICS 36
FIGURE 3 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR CANCER
TREATMENT, 2014-2020 36
EPIGENETIC PERSONALIZED MEDICINE FOR CANCER TREATMENT 37
HEMATOLOGICAL CANCERS 37
TABLE 5 FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES,
2004-2015 38
SOLID TUMORS 38
GASTRIC CANCER 39
LUNG CANCER 40
COLORECTAL CANCERS 40
EPIGENETIC PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS 40
HUNTINGTON'S DISEASE 41
ALZHEIMER'S DISEASE 42
DEPRESSION 42
MENTAL RETARDATION 43
PARKINSON'S DISEASE 44
EPIGENETIC PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASES 44
EPIGENETIC PERSONALIZED MEDICINE FOR OTHERS 45
MYELODYSPLASTIC SYNDROMES 45
TABLE 6 CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC
SYNDROMES (2015) 45
OBESITY 45
DIABETES 45
RHEUMATOID ARTHRITIS 46
MULTIPLE SCLEROSIS 46
TABLE 7 EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS
PATHOGENESIS 46
INFLAMMATORY BOWEL DISEASES 47
CHAPTER 6 EPIGENETIC THERAPIES 49
STEM CELL THERAPIES 49
DIABETES 49
MENTAL DISORDERS 49
SEASONAL AFFECTIVE DISORDER 49
UNIPOLAR DEPRESSION 50
DYSTHYMIA OR DYSTHYMIA DISORDER 50
ATYPICAL DEPRESSION 50
PSYCHOTIC DEPRESSION 50
CHAPTER 7 BIOMARKER TECHNIQUES 53
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION DNA
METHYLATION 53
CHROMATIN REMODELING 54
MIRNAS 54
miRNA Detection 54
MARKET DYNAMICS FOR EPIGENETIC DRUGS AND BIOMARKER DISCOVERY 55
DRIVERS 55
Increasing Prevalence of Cancer and Other Chronic Diseases 55
TABLE 8 GLOBAL CANCER INCIDENCES, 2012 56
Growing Global Geriatric Population Base 56
FIGURE 4 POPULATION AGE 65 AND OLDER, 2010-2030 (%) 57
Increasing Collaborations between Biotechnology and Pharmaceutical
Companies and Academic Research Institutes 58
TABLE 9 MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015 58
Presence of Funding Programs to Promote and Support Research and
Development 59
TABLE 10 KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED RandD,
2004-2015 59
Introduction of Technological Advancements 59
RESTRAINTS 60
Inefficiency to Identification and Validation of Biomarkers 60
Presence of Complicated Regulatory Framework 60
CHAPTER 8 EPIGENETIC NON-CANCER DIAGNOSIS 62
FIGURE 5 EPIGENOMIC ANALYSIS 62
NEURO 62
ALZHEIMER'S DISEASE 63
RESEARCH AND DEVELOPMENT 63
DEPRESSION 64
MENTAL RETARDATION 64
CARDIOVASCULAR DISEASE 65
TABLE 11 GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS) 65
FIGURE 6 POPULATION AFFECTED IN HIGH-, MIDDLE- AND LOW-INCOME
COUNTRIES BY TYPE OF HEART DISEASE, 2012 (%) 66
FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE PERCENTAGE, 2012 (%) 66
RESEARCH AND DEVELOPMENT IN EPIGENETICS CREATING HUGE SCOPE 67
FIGURE 8 EPIGENETIC ADVANCEMENT IN CARDIOVASCULAR DISEASES 67
HEART FAILURE 68
INFLAMMATORY AND AUTOIMMUNE DISEASE 69
RHEUMATOID ARTHRITIS 69
DIABETES 69
MULTIPLE SCLEROSIS 70
FIGURE 9 EPIGENETICS MECHANISM 70
INFLAMMATORY BOWEL DISEASES 71
LUPUS 71
RESEARCH AND DEVELOPMENT 72
DNA METHYLATION IN CANCER DETECTION 72
IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND
PREDICTION 73
MECHANISMS OF EPIGENETIC GENE SILENCING 73
CHAPTER 9 EPIGENETIC APPLICATIONS 76
EPIGENETICS DURING EARLY EMBRYONIC STAGES 76
PRE-IMPLANTATION REPROGRAMMING 76
Fusion and Cleavage 76
Demethylation and Remethylation in Early Embryos 76
Epigenetic Reprogramming in Later Development 77
Gene Expression and its Development in Clones and Technical
Contributions 77
GAMETOGENIC REPROGRAMMING 78
MITOCHONDRIAL HETEROPLASMY 78
IMPLICATIONS OF EPIGENETIC REPROGRAMMING ON ANIMAL HEALTH AND
FOOD CONSUMPTION RISKS 79
REPROGRAMMING FACTORS 80
EPIGENETIC PROFILE OF MESENCHYMAL STEM CELLS IN CULTURE 81
TABLE 12 INDICATIONS AND OUTCOMES 81
CHAPTER 10 EPIGENOMICS: REGIONAL ANALYSIS 84
OVERVIEW 84
NORTH AMERICA 84
FIGURE 10 NORTH AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS) 84
TABLE 13 NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020
($ MILLIONS) 85
TABLE 14 NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH
2020 ($ MILLIONS) 86
TABLE 15 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 86
TABLE 16 NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG
TECHNOLOGY, THROUGH 2020 ($ MILLIONS) 86
TABLE 17 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA,
THROUGH 2020 ($ MILLIONS) 87
TABLE 18 NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER
TREATMENT MARKET BY TYPE, THROUGH 2020 ($ MILLIONS) 87
TABLE 19 NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020
($ MILLIONS) 88
TABLE 20 NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE
BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 89
TABLE 21 NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE
FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 89
TABLE 22 NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE
FOR OTHERS, THROUGH 2020 ($ MILLIONS) 90
TABLE 23 NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($
MILLIONS) 90
TABLE 24 NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS) 91
TABLE 25 NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS
BIOMARKER IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS) 92
TABLE 26 NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 ($
MILLIONS) 92
TABLE 27 NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH
2020 ($ MILLIONS) 93
TABLE 28 NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET,
THROUGH 2020 ($ MILLIONS) 94
TABLE 29 NORTH AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE
DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS) 94
TABLE 30 NORTH AMERICAN EPIGENOMIC RESEARCH AND DEVELOPMENT MARKET,
THROUGH 2020 ($ MILLIONS) 95
ASIA-PACIFIC 96
FIGURE 11 ASIA-PACIFIC EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS) 96
TABLE 31 ASIA-PACIFIC EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($
MILLIONS) 97
TABLE 32 ASIA-PACIFIC EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH 2020 ($
MILLIONS) 97
TABLE 33 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($
MILLIONS) 98
TABLE 34 ASIA-PACIFIC EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY,
THROUGH 2020 ($ MILLIONS) 98
TABLE 35 ASIA-PACIFIC EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($
MILLIONS) 99
TABLE 36 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
CANCER TREATMENT, THROUGH 2020 ($ MILLIONS) 99
TABLE 37 ASIA-PACIFIC EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($
MILLIONS) 100
TABLE 38 ASIA-PACIFIC EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BY
THERAPEUTIC, THROUGH 2020 ($ MILLIONS) 100
TABLE 39 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 101
TABLE 40 ASIA-PACIFIC EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS) 101
TABLE 41 ASIA-PACIFIC EPIGENETIC THERAPY MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 102
TABLE 42 ASIA-PACIFIC BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS) 103
TABLE 43 ASIA-PACIFIC HISTONIC MODIFICATION AS A BIOMARKER IN CANCER
DETECTION MARKET, THROUGH 2020 ($ MILLIONS) 104
TABLE 44 ASIA-PACIFIC EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($
MILLIONS) 104
TABLE 45 ASIA-PACIFIC EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020
($ MILLIONS) 105
TABLE 46 ASIA-PACIFIC EPIGENETIC MARKET FOR CARDIOVASCULAR DIAGNOSIS,
THROUGH 2020 ($ MILLIONS) 105
TABLE 47 ASIA-PACIFIC EPIGENETIC MARKET FOR INFLAMMATORY AND
AUTOIMMUNE DISEASE DIAGNOSIS, THROUGH 2020 ($ MILLIONS) 106
TABLE 48 ASIA-PACIFIC EPIGENETIC MARKET FOR RESEARCH AND DEVELOPMENT,
THROUGH 2020 ($ MILLIONS) 107
EUROPE 108
FIGURE 12 EUROPE EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS) 108
TABLE 49 EUROPEAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($
MILLIONS) 109
TABLE 50 EUROPEAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH ($
MILLIONS) 109
TABLE 51 EUROPEAN EPIGENOMIC MARKET BY APPLICATION, THROUGH 2020 ($
MILLIONS) 110
TABLE 52 EUROPEAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY,
THROUGH 2020 ($ MILLIONS) 110
TABLE 53 EUROPEAN EPIGENOMIC MARKET BY APPLICATION AREA, THROUGH
2020 ($ MILLIONS) 110
TABLE 54 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
CANCER TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS) 111
TABLE 55 EUROPEAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($
MILLIONS) 111
TABLE 56 EUROPEAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE BASED
ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 112
TABLE 57 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 113
TABLE 58 EUROPEAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
OTHERS BY APPLICATION, THROUGH 2020 ($ MILLIONS) 113
TABLE 59 EUROPEAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($
MILLIONS) 114
TABLE 60 EUROPEAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS) 115
TABLE 61 EUROPEAN HISTONIC MODIFICATION AS BIOMARKER MARKET IN CANCER
DETECTION, THROUGH 2020 ($ MILLIONS) 115
TABLE 62 EUROPEAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($
MILLIONS) 116
TABLE 63 EUROPEAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH 2020 ($
MILLIONS) 116
TABLE 64 EUROPEAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET,
THROUGH 2020 ($ MILLIONS) 117
TABLE 65 EUROPEAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE DISEASE
DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS) 117
TABLE 66 EUROPEAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH 2020
($ MILLIONS) 118
LATIN AMERICA 119
FIGURE 13 LATIN AMERICAN EPIGENOMIC MARKET, 2014-2020 ($ MILLIONS) 119
TABLE 67 LATIN AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($
MILLIONS) 120
TABLE 68 LATIN AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH
2020 ($ MILLIONS) 120
TABLE 69 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 121
TABLE 70 LATIN AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY,
THROUGH 2020 ($ MILLIONS) 121
TABLE 71 LATIN AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 121
TABLE 72 LATIN AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER
TREATMENT BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS) 122
TABLE 73 LATIN AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($
MILLIONS) 123
TABLE 74 LATIN AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE
BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 123
TABLE 75 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE
FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 124
TABLE 76 LATIN AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE
FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS) 124
TABLE 77 LATIN AMERICAN EPIGENETIC THERAPY MARKET, THROUGH 2020 ($
MILLIONS) 125
TABLE 78 LATIN AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS) 126
TABLE 79 LATIN AMERICAN HISTONIC MODIFICATION AS BIOMARKER IN CANCER
DETECTION MARKET, THROUGH 2020 ($ MILLIONS) 126
TABLE 80 LATIN AMERICAN EPIGENETIC DIAGNOSIS MARKET, THROUGH 2020 ($
MILLIONS) 127
TABLE 81 LATIN AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH
2020 ($ MILLIONS) 127
TABLE 82 LATIN AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET,
THROUGH 2020 ($ MILLIONS) 128
TABLE 83 LATIN AMERICAN EPIGENETIC INFLAMMATORY AND AUTOIMMUNE
DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS) 129
TABLE 84 LATIN AMERICAN EPIGENETIC RESEARCH AND DEVELOPMENT, THROUGH
2020 ($ MILLIONS) 129
MIDDLE EAST AND AFRICA 130
FIGURE 14 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET, 2014-2020 ($
MILLIONS) 130
TABLE 85 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY PRODUCT,
THROUGH 2020 ($ MILLIONS) 131
TABLE 86 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY TECHNOLOGY,
THROUGH 2020 ($ MILLIONS) 131
TABLE 87 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION,
THROUGH 2020 ($ MILLIONS) 132
TABLE 88 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY CANCER DRUG
TECHNOLOGY, THROUGH 2020 ($ MILLIONS) 132
TABLE 89 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY APPLICATION AREA,
THROUGH 2020 ($ MILLIONS) 133
TABLE 90 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED
MEDICINE FOR CANCER TREATMENT BY TYPE, THROUGH 2020 ($ MILLIONS) 133
TABLE 91 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET BY SEGMENT,
THROUGH 2020 ($ MILLIONS) 134
TABLE 92 MIDDLE EAST AND AFRICA EPIGENOMIC MARKET FOR PERSONALIZED
MEDICINE BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 135
TABLE 93 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED
MEDICINE FOR NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 135
TABLE 94 MIDDLE EAST AND AFRICA EPIGENETIC MARKET FOR PERSONALIZED
MEDICINE FOR OTHERS BY DIAGNOSIS, THROUGH 2020 ($ MILLIONS) 135
TABLE 95 MIDDLE EAST AND AFRICA EPIGENETIC THERAPY MARKET, THROUGH
2020 ($ MILLIONS) 136
TABLE 96 MIDDLE EAST AND AFRICA BIOMARKER MARKET, THROUGH 2020 ($
MILLIONS) 137
TABLE 97 MIDDLE EAST AND AFRICA HISTONIC MODIFICATION AS BIOMARKER IN
CANCER DETECTION MARKET, THROUGH 2020 ($ MILLIONS) 138
TABLE 98 MIDDLE EAST AND AFRICA EPIGENETIC DIAGNOSIS MARKET, THROUGH
2020 ($ MILLIONS) 138
TABLE 99 MIDDLE EAST AND AFRICA EPIGENETIC NEURO DIAGNOSIS MARKET,
THROUGH 2020 ($ MILLIONS) 138
TABLE 100 MIDDLE EAST AND AFRICA EPIGENETIC CARDIOVASCULAR DIAGNOSIS
MARKET, THROUGH 2020 ($ MILLIONS) 139
TABLE 101 MIDDLE EAST AND AFRICA EPIGENETIC INFLAMMATORY AND
AUTOIMMUNE DISEASE DIAGNOSIS MARKET, THROUGH 2020 ($ MILLIONS) 140
TABLE 102 MIDDLE EAST AND AFRICA EPIGENETIC RESEARCH AND DEVELOPMENT,
THROUGH 2020 ($ MILLIONS) 141
CHAPTER 11 PRODUCT ANALYSIS 143
REAGENTS 143
FIGURE 15 GLOBAL EPIGENOMIC MARKET FOR REAGENTS, 2014-2020 ($ MILLIONS) 143
TABLE 103 GLOBAL EPIGENOMIC MARKET FOR REAGENTS BY REGION, THROUGH
2020 ($ MILLIONS) 144
KITS 144
FIGURE 16 GLOBAL EPIGENOMIC MARKET FOR KITS, 2014-2020 ($ MILLIONS) 144
TABLE 104 GLOBAL EPIGENOMIC MARKET FOR KITS BY REGION, THROUGH 2020 ($
MILLIONS) 146
INSTRUMENTS 146
FIGURE 17 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS, 2014-2020 ($
MILLIONS) 146
TABLE 105 GLOBAL EPIGENOMIC MARKET FOR INSTRUMENTS BY REGION,
THROUGH 2020 ($ MILLIONS) 147
ENZYMES 147
FIGURE 18 GLOBAL EPIGENOMIC MARKET FOR ENZYMES, 2014-2020 ($ MILLIONS) 147
TABLE 106 GLOBAL EPIGENOMIC MARKET FOR ENZYMES BY REGION, THROUGH
2020 ($ MILLIONS) 148
SERVICES 149
FIGURE 19 GLOBAL EPIGENOMIC MARKET FOR SERVICES, 2014-2020 ($ MILLIONS) 149
TABLE 107 GLOBAL EPIGENOMIC MARKET FOR SERVICES BY REGION, THROUGH
2020 ($ MILLIONS) 150
CHAPTER 12 ANALYSIS BY TECHNOLOGY 152
DNA METHYLATION 152
FIGURE 20 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION, 2014-2020 ($
MILLIONS) 152
TABLE 108 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION BY REGION,
THROUGH 2020 ($ MILLIONS) 153
HISTONE METHYLATION AND ACETYLATION 153
FIGURE 21 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND
ACETYLATION, 2014-2020 ($ MILLIONS) 153
TABLE 109 GLOBAL EPIGENOMIC MARKET IN HISTONE METHYLATION AND
ACETYLATION BY REGION, THROUGH 2020 ($ MILLIONS) 154
MICRORNA MODIFICATION 155
FIGURE 22 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION, THROUGH
2020 ($ MILLIONS) 155
TABLE 110 GLOBAL EPIGENOMIC MARKET IN MICRORNA MODIFICATION BY REGION,
THROUGH 2020 ($ MILLIONS) 155
CHAPTER 13 ANALYSIS BY APPLICATION 158
ONCOLOGY 158
FIGURE 23 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY, 2014-2020 ($ MILLIONS) 158
TABLE 111 GLOBAL EPIGENOMIC MARKET IN ONCOLOGY BY REGION, THROUGH
2020 ($ MILLIONS) 159
NON-ONCOLOGY 159
FIGURE 24 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, 2014-2020 ($
MILLIONS) 159
TABLE 112 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY, BY REGION,
THROUGH 2020 ($ MILLIONS) 160
CANCER DRUG TECHNOLOGY 161
DNA METHYLTRANSFERASE INHIBITORS 161
FIGURE 25 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE
INHIBITORS, 2014-2020 ($ MILLIONS) 161
TABLE 113 GLOBAL EPIGENOMIC MARKET IN DNA METHYLTRANSFERASE
INHIBITORS BY REGION, THROUGH 2020 ($ MILLIONS) 162
HISTONE DEACETYLASE INHIBITORS 162
FIGURE 26 GLOBAL EPIGENOMIC MARKET IN HISTONE DEACETYLASE INHIBITORS,
2014-2020 ($ MILLIONS) 162
TABLE 114 GLOBAL EPIGENOMIC MARKET IN NON-ONCOLOGY BY REGION,
THROUGH 2020 ($ MILLIONS) 163
APPLICATION AREAS 164
DIAGNOSIS 164
FIGURE 27 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS, 2014-2020 ($ MILLIONS) 164
TABLE 115 GLOBAL EPIGENOMIC MARKET IN DIAGNOSIS BY REGION, THROUGH
2020 ($ MILLIONS) 164
PROGNOSIS 165
FIGURE 28 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS) 165
TABLE 116 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS BY REGION, THROUGH
2020 ($ MILLIONS) 166
THERAPY OPTIMIZATION IN ROUTINE CLINICAL TREATMENT 166
FIGURE 29 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN
ROUTINE CLINICAL TREATMENT, 2014-2020 ($ MILLIONS) 166
TABLE 117 GLOBAL EPIGENOMIC MARKET FOR THERAPY OPTIMIZATION IN
ROUTINE CLINICAL TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS) 167
DRUG DISCOVERY 168
FIGURE 30 GLOBAL EPIGENOMIC MARKET IN PROGNOSIS, 2014-2020 ($ MILLIONS) 168
TABLE 118 GLOBAL EPIGENOMIC MARKET IN DRUG DISCOVERY BY REGION,
THROUGH 2020 ($ MILLIONS) 169
CHAPTER 14 ANALYSIS BY PERSONALIZED MEDICINES 171
FIGURE 31 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
CANCER TREATMENT, 2014-2020 ($ MILLIONS) 171
TABLE 119 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
CANCER TREATMENT BY REGION, THROUGH 2020 ($ MILLIONS) 172
FIGURE 32 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
NEUROLOGICAL DISORDERS, 2014-2020 ($ MILLIONS) 172
TABLE 120 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
NEUROLOGICAL DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 173
PERSONALIZED MEDICINE FOR CARDIOVASCULAR DISEASE 173
FIGURE 33 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
CARDIOVASCULAR DISEASE, 2014-2020 ($ MILLIONS) 174
TABLE 121 GLOBAL EPIGENOMIC MARKET IN PERSONALIZED MEDICINE FOR
CARDIOVASCULAR DISEASE, BY REGION, THROUGH 2020 ($ MILLIONS) 174
HEMATOLOGICAL CANCERS 175
FIGURE 34 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS,
2014-2020 ($ MILLIONS) 175
TABLE 122 GLOBAL EPIGENOMIC MARKET IN HEMATOLOGICAL CANCERS BY
REGION, THROUGH 2020 ($ MILLIONS) 176
Solid Tumors 176
FIGURE 35 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS, 2014-2020 ($
MILLIONS) 177
TABLE 123 GLOBAL EPIGENOMIC MARKET IN SOLID TUMORS BY REGION,
THROUGH 2020 ($ MILLIONS) 178
GASTRIC CANCER 178
FIGURE 36 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER, 2014-2020 ($
MILLIONS) 178
TABLE 124 GLOBAL EPIGENOMIC MARKET IN GASTRIC CANCER BY REGION,
THROUGH 2020 ($ MILLIONS) 179
LUNG CANCER 180
FIGURE 37 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER, 2014-2020 ($
MILLIONS) 180
TABLE 125 GLOBAL EPIGENOMIC MARKET IN LUNG CANCER BY REGION, THROUGH
2020 ($ MILLIONS) 181
PERSONALIZED MEDICINE FOR NEUROLOGICAL DISORDERS 181
HUNTINGTON'S DISEASE 181
FIGURE 38 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, 2014-2020
($ MILLIONS) 181
TABLE 126 GLOBAL EPIGENOMIC MARKET IN HUNTINGTON'S DISEASE, BY REGION,
THROUGH 2020 ($ MILLIONS) 182
ALZHEIMER'S DISEASE 182
FIGURE 39 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE, 2014-2020 ($
MILLIONS) 182
TABLE 127 GLOBAL EPIGENOMIC MARKET IN ALZHEIMER'S DISEASE BY REGION,
THROUGH 2020 ($ MILLIONS) 183
DEPRESSION 184
FIGURE 40 GLOBAL EPIGENOMIC MARKET IN DEPRESSION, 2014-2020 ($ MILLIONS) 184
TABLE 128 GLOBAL EPIGENOMIC MARKET IN DEPRESSION BY REGION, THROUGH
2020 ($ MILLIONS) 184
MENTAL RETARDATION 185
FIGURE 41 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION, 2014-2020 ($
MILLIONS) 185
TABLE 129 GLOBAL EPIGENOMIC MARKET IN MENTAL RETARDATION BY REGION,
THROUGH 2020 ($ MILLIONS) 186
PARKINSON'S DISEASE 186
FIGURE 42 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, 2014-2020 ($
MILLIONS) 186
TABLE 130 GLOBAL EPIGENOMIC MARKET IN PARKINSON'S DISEASE, BY REGION,
THROUGH 2020 ($ MILLIONS) 187
PERSONALIZED MEDICINE FOR OTHERS 187
MYELODYSPLASTIC SYNDROMES 187
FIGURE 43 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES,
2014-2020 ($ MILLIONS) 188
TABLE 131 GLOBAL EPIGENOMIC MARKET IN MYELODYSPLASTIC SYNDROMES BY
REGION, THROUGH 2020 ($ MILLIONS) 188
OBESITY 189
FIGURE 44 GLOBAL EPIGENOMIC MARKET IN OBESITY, 2014-2020 ($ MILLIONS) 189
TABLE 132 GLOBAL EPIGENOMIC MARKET IN OBESITY, BY REGION, THROUGH 2020
($ MILLIONS) 190
DIABETES 190
FIGURE 45 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS) 190
TABLE 133 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH
2020 ($ MILLIONS) 191
RHEUMATOID ARTHRITIS 191
FIGURE 46 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020
($ MILLIONS) 191
TABLE 134 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION,
THROUGH 2020 ($ MILLIONS) 192
MULTIPLE SCLEROSIS 193
FIGURE 47 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS, 2014-2020 ($
MILLIONS) 193
TABLE 135 GLOBAL EPIGENOMIC MARKET IN MULTIPLE SCLEROSIS BY REGION,
THROUGH 2020 ($ MILLIONS) 194
INFLAMMATORY BOWEL DISEASES 194
FIGURE 48 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES,
2014-2020 ($ MILLIONS) 194
TABLE 136 GLOBAL EPIGENOMIC MARKET IN INFLAMMATORY BOWEL DISEASES BY
REGION, THROUGH 2020 ($ MILLIONS) 195
LUPUS 195
FIGURE 49 GLOBAL EPIGENOMIC MARKET IN LUPUS, 2014-2020 ($ MILLIONS) 195
TABLE 137 GLOBAL EPIGENOMIC MARKET IN LUPUS BY REGION, THROUGH 2020 ($
MILLIONS) 196
STEM CELL THERAPIES 197
FIGURE 50 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES, 2014-2020 ($
MILLIONS) 197
TABLE 138 GLOBAL EPIGENOMIC MARKET IN STEM CELL THERAPIES BY REGION,
THROUGH 2020 ($ MILLIONS) 197
TISSUE RE-ENGINEERING 198
FIGURE 51 GLOBAL EPIGENOMIC MARKET IN TISSUE RE-ENGINEERING, 2014-2020
($ MILLIONS) 198
TABLE 139 GLOBAL EPIGENOMIC MARKET IN TISSUE REENGINEERING BY REGION,
THROUGH 2020 ($ MILLIONS) 199
DIABETES 199
FIGURE 52 GLOBAL EPIGENOMIC MARKET IN DIABETES, 2014-2020 ($ MILLIONS) 199
TABLE 140 GLOBAL EPIGENOMIC MARKET IN DIABETES BY REGION, THROUGH
2020 ($ MILLIONS) 200
RHEUMATOID ARTHRITIS 201
FIGURE 53 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS, 2014-2020
($ MILLIONS) 201
TABLE 141 GLOBAL EPIGENOMIC MARKET IN RHEUMATOID ARTHRITIS BY REGION,
THROUGH 2020 ($ MILLIONS) 201
MENTAL DISORDERS 202
FIGURE 54 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS, 2014-2020 ($
MILLIONS) 202
TABLE 142 GLOBAL EPIGENOMIC MARKET IN MENTAL DISORDERS BY REGION,
THROUGH 2020 ($ MILLIONS) 203
CARDIAC DYSFUNCTION 203
FIGURE 55 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION, 2014-2020
($ MILLIONS) 203
TABLE 143 GLOBAL EPIGENOMIC MARKET IN CARDIAC DYSFUNCTION BY REGION,
THROUGH 2020 ($ MILLIONS) 204
CANCER 204
FIGURE 56 GLOBAL EPIGENOMIC MARKET IN CANCER, 2014-2020 ($ MILLIONS) 205
TABLE 144 GLOBAL EPIGENOMIC MARKET IN CANCER BY REGION, THROUGH 2020
($ MILLIONS) 205
BIOMARKER DISCOVERY: DNA METHYLATION FOR CANCER DETECTION 206
FIGURE 57 GLOBAL EPIGENOMIC MARKET IN DNA METHYLATION FOR CANCER
DETECTION, 2014-2020 ($ MILLIONS) 206
TABLE 145 GLOBAL EPIGENOMIC MARKET IN BIOMARKER DISCOVERY: DNA
METHYLATION FOR CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS) 207
HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION 207
FIGURE 58 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS
BIOMARKER IN CANCER DETECTION, 2014-2020 ($ MILLIONS) 207
TABLE 146 GLOBAL EPIGENOMIC MARKET IN HISTONIC MODIFICATION AS
BIOMARKER IN CANCER DETECTION BY REGION, THROUGH 2020 ($ MILLIONS) 208
FIGURE 59 GLOBAL EPIGENOMICS MARKET IN CHROMATIN REMODELING,
2014-2020 ($ MILLIONS) 208
TABLE 147 GLOBAL EPIGENOMIC MARKET IN CHROMATIN REMODELING BY REGION,
THROUGH 2020 ($ MILLIONS) 209
NONCODING RNAS 210
FIGURE 60 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS, 2014-2020 ($
MILLIONS) 210
TABLE 148 GLOBAL EPIGENOMIC MARKET IN NONCODING RNAS BY REGION,
THROUGH 2020 ($ MILLIONS) 211
FIGURE 61 GLOBAL EPIGENOMIC MARKET IN MIRNAS, 2014-2020 ($ MILLION) 211
TABLE 149 GLOBAL EPIGENOMIC MARKET IN MIRNAS BY REGION, THROUGH 2020
($ MILLIONS) 212
CHAPTER 15 COMPANY PROFILES 214
ABBOTT LABORATORIES 214
TABLE 150 ABBOTT PRODUCT PORTFOLIO 214
TABLE 151 ABBOTT RECENT DEVELOPMENTS 214
AFFYMETRIX 214
TABLE 152 AFFYMETRIX PRODUCT PORTFOLIO 215
TABLE 153 AFFYMETRIX RECENT DEVELOPMENTS 215
AGILENT TECHNOLOGIES 215
TABLE 154 AGILENT PRODUCT PORTFOLIO 215
TABLE 155 AGILENT'S RECENT DEVELOPMENTS 216
ASTELLAS PHARMACEUTICALS 216
TABLE 156 ASTELLAS PHARMACEUTICALS PRODUCT PORTFOLIO 216
TABLE 157 ASTELLAS PHARMACEUTICALS RECENT DEVELOPMENTS 217
BAYER AG 217
TABLE 158 BAYER PRODUCT PORTFOLIO 217
TABLE 159 BAYER RECENT DEVELOPMENTS 218
BIO VISION 218
TABLE 160 BIO VISION PRODUCT PORTFOLIO 218
TABLE 161 BIO VISION RECENT DEVELOPMENTS 218
CELGENE CORP. 219
TABLE 162 CELGENE PRODUCT PORTFOLIO 219
EMD MILLIPORE 219
TABLE 163 EMD MILLIPORE PRODUCT PORTFOLIO 220
TABLE 164 EMD MILLIPORE RECENT DEVELOPMENTS 220
EPIGENOMICS AG 220
TABLE 165 EPIGENOMICS PRODUCT PORTFOLIO 220
TABLE 166 EPIGENOMICS RECENT DEVELOPMENTS 221
EPIGENTEX 221
TABLE 167 EPIGENTEK PRODUCT PORTFOLIO 221
TABLE 168 EPIGENTEK RECENT DEVELOPMENTS 221
ENVIVO PHARMACEUTICALS (FORUM PHARMACEUTRICALS) 222
GILEAD SCIENCES 222
TABLE 169 GILEAD SCIENCES PRODUCT PORTFOLIO 222
TABLE 170 GILEAD SCIENCES RECENT DEVELOPMENTS 223
GLAXOSMITHKLINE 223
TABLE 171 GLAXOSMITHKLINE PRODUCT PORTFOLIO 223
ILLUMINA INC. 223
TABLE 172 ILLUMINA PRODUCT PORTFOLIO 224
TABLE 173 ILLUMINA RECENT DEVELOPMENTS 224
JOHNSON and JOHNSON 224
TABLE 174 JOHNSON and JOHNSON PRODUCT PORTFOLIO 225
KARUS THERAPEUTICS LIMITED 225
TABLE 175 KARUS THERAPEUTICS PRODUCT PORTFOLIO 225
LABORATORY CORP. OF AMERICA HOLDINGS 225
TABLE 176 LABCORP PRODUCT PORTFOLIO 226
TABLE 177 LABCORP RECENT DEVELOPMENTS 226
LES LABORATOIRES SERVIER 226
TABLE 178 LES LABORATOIRES SERVIER RECENT DEVELOPMENTS 226
MERCK SHARP and DOHME 227
NATUREWISE BIOTECH and MEDICALS CORP. 227
NOVARTIS PHARMA AG 227
TABLE 179 NOVARTIS PRODUCT PORTFOLIO 228
TABLE 180 NOVARTIS RECENT DEVELOPMENTS 228
ONCOLYS BIOPHARMA INC. 228
TABLE 181 ONCOLYS BIOPHARMA PRODUCT PORTFOLIO 229
TABLE 182 ONCOLYS BIOPHARMA RECENT DEVELOPMENTS 229
ORCHID CHEMICALS and PHARMACEUTICALS LIMITED 229
TABLE 183 ORCHID CHEMICALS and PHARMACEUTICALS PRODUCT PORTFOLIO 230
PROGEN PHARMACEUTICALS LIMITED 230
TABLE 184 PROGEN PHARMA PRODUCT PORTFOLIO 230
QUEST DIAGNOSTICS 230
TABLE 185 QUEST DIAGNOSTICS PRODUCT PORTFOLIO 231
TABLE 186 QUEST DIAGNOSTICS RECENT DEVELOPMENTS 231
ROCHE HOLDING AG 231
TABLE 187 ROCHE'S PRODUCT PORTFOLIO 232
TABLE 188 ROCHE'S RECENT DEVELOPMENTS 232
RUBICON GENOMICS 232
TABLE 189 RUBICON GENOMICS PRODUCT PORTFOLIO 233
TABLE 190 RUBICON GENOMICS RECENT DEVELOPMENTS 233
TAKEDA PHARMACEUTICAL COMPANY LIMITED 233
TABLE 191 TAKEDA PHARMACEUTICALS PRODUCT PORTFOLIO 234
CHAPTER 16 PATENT ANALYSIS 236
LIST OF PATENTS 236
U.S. 236
TABLE 192 U.S. PATENTS, 2011-JULY 2015 236
EUROPEAN AND JAPANESE PATENTS 242
TABLE 193 EUROPEAN AND JAPANESE PATENTS, 2011-JULY 2015 242
JAPANESE PATENTS 242
TABLE 194 JAPANESE PATENTS, 2011--NOVEMBER 2014 242

LIST OF TABLES

SUMMARY TABLE GLOBAL EPIGENOMIC MARKET BY REGION, THROUGH 2020 ($
MILLIONS) 6
TABLE 1 U.S. FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES 13
TABLE 2 SELECTED EPIGENETIC THERAPIES IN CLINICAL DEVELOPMENT 15
TABLE 3 EPIGENETIC DRUG CLASSIFICATION WITH THERAPEUTIC POTENTIAL 21
TABLE 4 CLASSIFICATION ACCORDING TO POTENTIAL THERAPEUTIC USES AND
DEVELOPMENTAL PHASES, 2005-2015 23
TABLE 5 FOOD AND DRUG ADMINISTRATION-APPROVED EPIGENETIC THERAPIES,
2004-2015 38
TABLE 6 CLINICAL PICTURE OF PERSONALIZED MEDICINE IN MYELODYSPLASTIC
SYNDROMES (2015) 45
TABLE 7 EPIGENETIC MECHANISMS IMPLICATED IN MULTIPLE SCLEROSIS
PATHOGENESIS 46
TABLE 8 GLOBAL CANCER INCIDENCES, 2012 56
TABLE 9 MAJOR COLLABORATIONS IN THE EPIGENETIC MARKET, 2011-2015 58
TABLE 10 KEY GLOBAL ORGANIZATIONS FUNDING EPIGENOMICS RELATED RandD,
2004-2015 59
TABLE 11 GLOBAL IMPACT OF CARDIOVASCULAR DISEASE, 2013 (MILLIONS) 65
TABLE 12 INDICATIONS AND OUTCOMES 81
TABLE 13 NORTH AMERICAN EPIGENOMIC MARKET BY PRODUCT, THROUGH 2020 ($
MILLIONS) 85
TABLE 14 NORTH AMERICAN EPIGENOMIC MARKET BY TECHNOLOGY, THROUGH
2020 ($ MILLIONS) 86
TABLE 15 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 86
TABLE 16 NORTH AMERICAN EPIGENOMIC MARKET BY CANCER DRUG TECHNOLOGY,
THROUGH 2020 ($ MILLIONS) 86
TABLE 17 NORTH AMERICAN EPIGENOMIC MARKET BY APPLICATION AREA,
THROUGH 2020 ($ MILLIONS) 87
TABLE 18 NORTH AMERICAN EPIGENETIC PERSONALIZED MEDICINE FOR CANCER
TREATMENT MARKET BY TYPE, THROUGH 2020 ($ MILLIONS) 87
TABLE 19 NORTH AMERICAN EPIGENOMIC MARKET BY SEGMENT, THROUGH 2020 ($
MILLIONS) 88
TABLE 20 NORTH AMERICAN EPIGENOMIC MARKET FOR PERSONALIZED MEDICINE
BASED ON THERAPEUTICS, THROUGH 2020 ($ MILLIONS) 89
TABLE 21 NORTH AMERICA EPIGENETIC MARKET FOR PERSONALIZED MEDICINE FOR
NEUROLOGICAL DISORDERS, THROUGH 2020 ($ MILLIONS) 89
TABLE 22 NORTH AMERICAN EPIGENETIC MARKET FOR PERSONALIZED MEDICINE
FOR OTHERS, THROUGH 2020 ($ MILLIONS) 90
TABLE 23 NORTH AMERICAN EPIGENETIC THERAPIES MARKET, THROUGH 2020 ($
MILLIONS) 90
TABLE 24 NORTH AMERICAN BIOMARKER MARKET, THROUGH 2020 ($ MILLIONS) 91
TABLE 25 NORTH AMERICAN MARKET FOR HISTONIC MODIFICATION AS BIOMARKER
IN CANCER DETECTION, THROUGH 2020 ($ MILLIONS) 92
TABLE 26 NORTH AMERICAN EPIGENETIC DIAGNOSTIC MARKET, THROUGH 2020 ($
MILLIONS) 92
TABLE 27 NORTH AMERICAN EPIGENETIC NEURO DIAGNOSIS MARKET, THROUGH
2020 ($ MILLIONS) 93
TABLE 28 NORTH AMERICAN EPIGENETIC CARDIOVASCULAR DIAGNOSIS MARKET,

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Diabetes Statistics in the UK

  • November 2016
    9 pages
  • Therapy  

    Statins  

    Diabetes  

  • United Kingdom  

View report >

Infectious Disease Statistics

  • November 2016
    12 pages
  • Infectious Dise...  

    Therapy  

  • Niger  

    Kenya  

    Africa  

View report >

Influenza Statistics in the US

  • November 2016
    6 pages
  • Infectious Dise...  

    Influenza  

  • United States  

View report >

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.